Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Swing trends are excellent, takes time to clearly identify despite various tools in charting available,but once identified,
(IMO)is the best trading style for an investor.
are you long or day trading
the best advice I was ever given "the market will never do what you want it to do." Know what you want in any investments, cut your loses if you can't achieve it and move on.
www.PositiveIDcorp.com Page 13 of 26
March 2013
Chart IV. Anticipated BioWatch Generation 3 Timeline and Rollout
Chart IV above illustrates the anticipated timeline and rollout of the BioWatch Generation 3 program. With the draft Stage 1 RFP issued this past January, the next major milestone will be the final RFP expected by June 30th. This could then lead to the award of Stage 1 by the end of 2013.
With recent developments as noted earlier with Syria this time line could very well be moved up(IMO)
STRONG BUY and LONG
Leading Technology and Market Position.
PositiveID’s M-BAND
The M-BAND is positioned to capitalize on
BioWatch Generation 3, which is the U.S.
Government’s $3.1 billion program to detect
the release of pathogens into the air as
part of a defense against po
tential terrorist attacks on ma
jor American cities. The
Company’s M-BAND is one of only two known technologies capable of addressing the
requirements of BioWatch Gen-3, and the
only one to complete field-testing both
domestically and internationally in DHS’ BAND program.
The significance of Today's news (IMO)
"Quote"Bio-Detection Market
The Bio-detection market has seen a surge in funding over the past decade. This increased
attention to bio-surveillance can be directly attributed to events that occurred towards the
beginning of the 21st century. The Anthrax scare in 2001, the SARS outbreak in 2003, the ricin
letters in 2004 and the H1N1 health crisis in 2009, and most recently the concern over Syrian
chemical weapons, have confirmed to the domestic and
global community that threats of infectious
disease and bioterrorism are real and substantial. The urgent requirement for public healthcare
and homeland security agencies to institute an early
detection system for bio-terrorist attacks and
infectious disease outbreaks is a main driver of the increasing bio-detection market, which is
forecasted by Homeland Security Research Corp. ("HSRC"), to reach a cumulative $22.8 billion in
market value between 2012-2016.
http://www.globenewswire.com/Tracker?data=mxk5PKKaDco-misb14cvQBZpuM5NRnqN8U07_q5XCm6bCLYx9bExhMraPtVQs6_CTWZ5N88ocCG3U40RqMTlYgyAk6g2GrqvQO1CsIgLXebSOd4t7LHECG0Hpr3SEuxTwWzuvb7Pba6AakUhR3M_M4LqQlvIMougZay743WowPOr1Iok8cFgdP0QuDtdkJD07miggwRyiIfwNzpjKWwfm1HqHy7c3XcjP2WqOIF6i6k2eb51E5fhFMj5psOjMXWW1xsWPiNtVoyQZIuaYWAJwk6kzlCEdNBg7dN6TsXemPI%3D
my guess is all this is defining the relationship because the contracts are on the table as we speak.(IMO)
The license agreement provides Boeing the exclusive license to manufacture and sell PositiveID's M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector for the U.S. Department of Homeland Security's ("DHS") BioWatch Generation 3 opportunity, as well as other opportunities (government or commercial) that may arise in the North American market. Under the teaming agreement, PositiveID will retain exclusive rights to serve as the reagent and assay supplier of the M-BAND systems to Boeing in the U.S. market. PositiveID will also retain the right to sell M-BAND units, reagents and assays in international markets.
PositiveID's M-BAND, developed under contract for DHS Science and Technology Division, is a bioaerosol monitor with fully integrated systems with sample collection, processing and detection modules that continuously analyze air samples for the detection of bacteria, viruses, and toxins. Results from individual M-BAND instruments are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments in the aggregate.
William J. Caragol, Chairman and CEO of PositiveID, stated, "We are very proud to team with Boeing on the BioWatch opportunity and look forward to being a part of a strong team that exceeds the expectations of our customers."
Entry into a Material Definitive Agreement
On March 18, 2013, PositiveID Corporation, a Delaware corporation (“PositiveID”), entered into an Intercreditor and Non-Disturbance Agreement (the “Agreement”) among PositiveID and MicroFluidic Systems; VeriGreen Energy Corporation, Steel Vault Corporation, IFTH NY Sub, Inc., and IFTH NJ Sub, Inc.; The Boeing Company (“Boeing”); and TCA Global Credit Master Fund, LP (“TCA”). The Agreement sets forth the agreement of Boeing and TCA as to their respective rights and obligations with respect to the Boeing Collateral (as defined below) and the TCA Collateral (as defined below) and their understanding relative to their respective positions in the Boeing Collateral and the TCA Collateral.
The Boeing Collateral includes, among other things, all Intellectual Property Rights (as defined in the Agreement) in the MBAND Technology (as defined in the Agreement), including without limitation certain patents and patent applications set forth in the Agreement. The TCA Collateral includes any and all property and assets of PositiveID. The liens of Boeing on the Boeing Collateral are senior and prior in right to the liens of TCA on the Boeing Collateral and such liens of TCA on the Boeing Collateral are junior and subordinate to the liens of Boeing on the Boeing Collateral.
A copy of the Agreement will be filed as an Exhibit to PositiveID’s Annual Report on Form 10-K for the year ended December 31, 2012. The description of certain terms of the Agreement set forth herein do not purport to be complete and are qualified in their entirety by the provisions of such Agreement.
Can anyone confirm if this year will be as last Annual Meeting of Stockholders of PositiveID Corporation, or the Company, which will be held on May 21, 2012,
Today's filing is a significant step for PSID
The prospectus form that a company is required to file, detailing the information that created a significant change from previously-supplied information provided in the company's prior prospectus filed with the SEC. Companies are required to file prospectus form 424B3 in accordance with Rule 424(b)(3) of the Securities Exchange Act of 1933.
Investopedia Says:
The Securities Exchange Act of 1933 was created to help investors make informed decisions by requiring securities issuers to complete and file registration statements (including financial and material information) with the SEC before making an issue available for purchase by the public. Often, registration statements filings required under the Securities Exchange Act of 1933 are also registration statements under the Investment Company Act of 1940.
Read more: http://www.answers.com/topic/sec-form-424b3#ixzz2OK95WFgy
Do Your DD on artificial pancreas closed loop systems and see the patents PSID holds and license of our iglucose wireless diabetes management technology,CNN reported we are at the cusp at this point. The potential of PSID of it's successful development of a glucose-sensing system,an integral component of a closed loop artificial pancreas.
Long And Strong Buy
No R/S at least not at this point.
Hold on to your stake in your investment.
All investors wants a return on their investments. PSID is in a position presently to soar to new highs. Proposal to split the stock does not benefit shareholders at it's current price point under .02cents per share.
The stock is about to move and move strong based upon all that we know at this point in time(IMO) a R/S would take away the current position of any shareholder stake in the company. Any future point if you wanted to add to your position you would have to pay a high premium 10:1 or 25:1 for the share. We who currently held our shares to give it up would be shortsighted of our investment.
No R/S
Long And Strong Buy
Recent Development – Boeing License
Deal Terms
A License Agreement and a Teaming Agreement with The
Boeing Company
Boeing becomes the exclusive manufacturer and distributor
of M-BAND units (in North America – except
SAIC contract with DTRA) – Exclusive for the $3.1B BioWatch Gen-3 contract, expected beginning in 2013
PositiveID is exclusive provider of
monthly
reagents/assays to Boeing for any M-BAND units built and sold
Boeing pays PositiveID $2.5 million license fee in December
2012-April 2013
Why It Is Important
PositiveID teams with Boeing, a Fortune 50 company, with significant presence in DHS and DoD, and
experience in large system implementation
PositiveID maintains position as the exclusive provider of reagents and assays
PositiveID maintains full rights to M-BAND and monthly reagents/assays in SAIC/DTRA contract, Europe,
Asia, Middle East
Recurring revenue from reagents/assays will provide PositiveID a long-term annuity
PositiveID Market Opportunity
BioWatch Gen-3 procurement anticipates 2,500 units to be
deployed over 2013-2017; the 2,500 units will
require monthly reagent/assay replacement (the “razor blade”)
2,500 units will provide recurring revenue base of between $90-120M revenue annually at 15-20% margins
The U.S. market non-BioWatch (bases and embassies) should be of like size to BioWatch
Europe/Asia/Middle East markets could be significantly larger than U.S. market
PositiveID signed a teaming agreement with a large government contractor to pursue the Defense Threat Reduction Agency ("DTRA") Indefinite Delivery/Indefinite Quantity Multiple Award Contracts
PSID entered into a license agreement and a teaming agreement with The Boeing Company ("Boeing"), including a license fee to PositiveID of $2.5 million.
The license agreement provides Boeing the exclusive license to manufacture and sell PositiveID's M-BAND (Microfluidics-based Bioagent Networked Detector) airborne bio-threat detector for the U.S. Department of Homeland Security's ("DHS") BioWatch Generation 3 opportunity, as well as other opportunities (government or commercial) that may arise in the North American market. Under the teaming agreement, PositiveID will retain exclusive rights to serve as the reagent and assay supplier of the M-BAND systems to Boeing in the U.S. market. PositiveID will also retain the right to sell M-BAND units, reagents and assays in international markets.
My point at this stage is let the market decide the price action No R/S determined before annual meeting.
After which the BOD can ask shareholders to split the stock.
Board Discretion to Implement the Reverse Stock Split
Should we receive the required stockholder approval of Proposal 1 at the 2013 Special Meeting of Stockholders, our Board of Directors will have the authority to file the amendment to our Certificate of Incorporation with the Secretary of State of the State of Delaware and thereby implement the reverse stock split. The Board of Directors will have the authority to take such action at any time prior to our 2013 Annual Meeting of Stockholders. The Board of Directors intends to take such action only upon a determination by the Board of Directors that such action is in our and our stockholders’ best interests. Such determination shall be based upon a number of factors, including:
·
the then-existing and expected trading prices for our common stock;
·
the existing and expected marketability and liquidity of our common stock; and
·
the then-prevailing market conditions.
Notwithstanding receipt of the required stockholder approval of Proposal 1 at the 2013 Special Meeting of Stockholders, our Board of Directors may, in its sole discretion, abandon the proposed amendment to our Certificate of Incorporation and determine not to effect the reverse stock split, as permitted under Section 242(c) of the Delaware General Corporation Law. If the Board of Directors determines not to implement the reverse stock split prior to the 2013 Annual Meeting of Stockholders, we would be required, once again, to seek stockholder approval to implement a reverse stock split.
My feelings about this R/S is this I personally don't like companies that does this as was highlighted in someone's post the ratio of being successful is slim.
The facts are however,Management has proposed this to us, as it's shareholders..we have a decision to vote for it or against it...
They have presented both the upside and downside of the arguments to do a R/S.
The question most asks is the timing of this and the effects on the PPS.(We can speculate on the reasons until they are confirmed.)
My thoughts are...
Only and Only until the PPS is at the point that makes the most sense... then... Management would execute the R/S to propel the stock to reach the big board
I would look to see some analysts on PSID thus giving an indication the R/S is imminent...Just My Thoughts
I'm Long And Still Stong Buy.
PSID is in a unique position Not every day an investment of this magnitude comes along with it's current price.
Let buy your argument how do you propose listing on the main boards and attraction of institutional investors who never looks at anything under $3-$5 Range And $5-$10 range
when we consider all the cards on the table thus far
PSID has at this point in time reached where "expected contract" is soon to be announced.My thoughts are that it would be a missed opportunity and negligent on it's part not to increase shareholders value, institutional buyers are needed, at this point.
Rationale for a Reverse Stock Split TO BE HELD ON APRIL 18, 2013
Our Board of Directors has unanimously adopted a resolution approving, declaring advisable and recommending to the stockholders for their approval a proposal to authorize the Board of Directors to amend our Second Amended and Restated Certificate of Incorporation, as amended, which we will refer to as the Certificate of Incorporation, to effect a reverse stock split of our issued and outstanding common stock at a ratio in the range of 1-for-10 to 1-for-25.
1:A reverse stock split by a publicly traded company reduces the number of shares outstanding, but leaves the market capitalization of the company the same, which results in an increase in the price per share of the company’s stock. Put another way, after a reverse stock split, the enterprise value of the company is spread over fewer shares and so the per share price of the stock will be higher.
2:The Board of Directors believes implementing a reverse stock split is likely to increase the market price for PositiveID
3This, we believe, could provide a number of potential advantages.
4:We believe that the reverse stock split could enhance the appeal of our common stock to the financial community, including institutional investors, and the general investing public. We believe that a number of institutional investors and investment funds are reluctant to invest in lower priced securities and that brokerage firms may be reluctant to recommend lower priced stock to their clients, which may be due in part to a perception that lower-priced securities are less promising as investments, are less liquid in the event that an investor wishes to sell his, her or its shares, or are less likely to be followed by institutional securities research firms.
I believe we have a company who is interested in protecting this great nation and it's people and at the same time investors can add value to their portfolios.
I am long and strong buy.
an update on the progress of its strategic plan to refocus the Company on its patented and patent pending technologies to serve the estimated $3.1 Billion BioWatch Generation 3 program, which is designed to protect the American public from a biological attack. This update is intended to present stockholders with a review of major accomplishments for 2012 and an outlook for 2013.
1: We achieved major milestones by signing agreements with (a) with a large strategic partner (b)with a large government contractor
2: DHS released a draft request for proposal ("RFP") for Stage 1 of BioWatch Generation 3
3: The final RFP for Stage 1 of BioWatch Generation 3 is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th.
4: The Stage 1 contract is expected period of 18 months,
5: full roll-out (Stage 2) is estimated at $3.1 billion over the next five years.
Any idea who these may be?
-- PositiveID is in discussions with additional potential strategic partners to support the deployment of its technologies and access new market opportunities.
Any revenue stream developing in regards to supply & reagents?
PositiveID retained exclusive rights to serve as the reagent and assay supplier of M-BAND systems to its partner in the U.S. market, and also retained the right to sell M-BAND units, reagents and assays in international markets.
C.E.O.mentioned in his overview
As we await the final request for proposal ("RFP") for Stage 1 of BioWatch Generation 3, we believe we are effectively positioned to commercialize our technologies for homeland defense and deliver stockholder value."
Am I correct to understand the next move is production with Boeing?
Long & Strong Buy